GE Builds Single-Use Kit Manufacturing Facility in Switzerland
GE Healthcare Life Sciences’ new facility for cell and gene processing supplies will be open in 2022.
GE Healthcare Life Sciences is building a new 7360-m2 facility in Grens, Switzerland, in the new Signy Park, for the manufacture of single-use kits for the company’s Sepax and Sefia cell processing systems. The facility, being designed and built by Nemaco, is expected to be fully operational in 2022, and will complement the company’s existing manufacturing facilities, the company announced in a Jan. 21, 2020 press release.
The new site will also house a Center of Excellence with advanced cell and gene therapy manufacturing facilities and will serve as a base for European customer training and educational initiatives. The new facility will be able to house up to 200 employees and will also support a growing R&D team and other subject matter experts.
“With more than 900 regenerative companies worldwide, we see increased demand for our resources and expertise. Our Swiss operations are critical to the success of our cell and gene therapy customers, so this new facility will allow us to accelerate capacity and provide a single location where our research, engineering, and service teams can thrive,” said Emmanuel Ligner, president and CEO, GE Healthcare Life Sciences, in the press release.
“From clinical trials to commercialization, regenerative medicine is going to transform global healthcare. This new facility will allow us to meet anticipated global demand while simultaneously developing the next generation of products that will accelerate the commercialization and industrialization of cell and gene therapies,” said Catarina Flyborg, general manager, Cell and Gene Therapy, GE Healthcare Life Sciences, in the press release.
Source: GE Healthcare Life Sciences
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
